ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 215

Clinical Pharmacist As Part of the Interprofessional Team Improves Quality of Care in Patients with Rheumatic Disease

Jessica Farrell1, Lee S. Shapiro1 and Mitchell Miller2, 1The Center for Rheumatology, Albany, NY, 2Albany College of Pharmacy and Health Sciences, Albany, NY

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Counseling, drug safety, drug safety monitoring, medication and pharmacists

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: ARHP Health Services Research Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Successful multidisciplinary models exist for the management of chronic diseases such as diabetes, cardiovascular disease, infectious diseases, kidney disease and psychiatric illnesses. A multidisciplinary team including a pharmacist in the ambulatory care setting has shown to improve patient and population outcomes for various chronic disease states. Rheumatology healthcare providers recognize the burden of rheumatic disease requires an integrated, multidisciplinary team including a pharmacist. Recent data suggests pharmacists can improve adherence and health outcomes in the management of gout. This type of pharmacist-led intervention can easily be extrapolated to other rheumatic diseases. The addition of a pharmacist to the healthcare team can have many benefits, including improving patient compliance and education, serving as a drug information resource, and obtaining insurance coverage. This includes establishing patient relationships, gathering medication histories, preventing, identifying and resolving medication related problems, educating patients and other healthcare providers, monitoring patients and medication effects, and contributing to continuity of care for all patients. Clinical pharmacy services at The Center for Rheumatology (TCFR) have expanded over the past 8 years.

Methods:

The aim of our project is to 1) provide billable pharmacy consult services which systematize practice-wide medication initiation and safety monitoring, 2) provide additional support to practice-wide procedures/protocols related to medication therapy and insurance authorizations, 3) provide evidence of improved patient and population outcomes when a pharmacist is part of the interdisciplinary team in a rheumatology practice, 4) serve as a business model of an innovative practice in pharmacy. Outcome measures include number of reimbursable visits, assessments of medication prior authorizations, denials and peer-to-peer calls, and provider, support staff and patient surveys.

Results:

The pharmacist provides face-to-face problem/medication focused visits which are reimbursed through incident-to billing. Visits are focused on initiation and safety monitoring for high-risk DMARD and osteoporosis therapies. The drug information consult services and insurance authorization assistance have been shown to save providers and support staff time, ranging from 1-3+ hours per week per provider. Providers report the addition of a pharmacist allows them to provide a higher level of care focused on medication therapy and safety, and helps improves patient compliance and anxiety related to medications.

Conclusion:

The addition of a pharmacist to the multidisciplinary team in a rheumatology practice can improve the quality of care delivered to patients, specifically related to medication safety and access by assisting in the prior authorization process and serving as patient advocates. The addition of clinical pharmacy services sets the practice apart from others by improving patient care and serving as an innovative business model for rheumatology practices to include a clinical pharmacist as part of their healthcare team.


Disclosure: J. Farrell, None; L. S. Shapiro, None; M. Miller, None.

To cite this abstract in AMA style:

Farrell J, Shapiro LS, Miller M. Clinical Pharmacist As Part of the Interprofessional Team Improves Quality of Care in Patients with Rheumatic Disease [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/clinical-pharmacist-as-part-of-the-interprofessional-team-improves-quality-of-care-in-patients-with-rheumatic-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-pharmacist-as-part-of-the-interprofessional-team-improves-quality-of-care-in-patients-with-rheumatic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology